Abstract Library

#3893 Pancreatic neuroendocrine tumor associated hypophosphatemia due to tumor-induced osteomalacia – A case report

Introduction: Tumor-induced osteomalacia (TIO) is a rare syndrome characterised by hypophosphataemia and osteomalacia with renal phosphate wasting caused by elevated levels of fibroblast growth factor 23 (FGF23) in the setting of tumor. The primary tumor is typically found in bone or soft tissue.

Conference:

Presenting Author:

Authors: Storan D, Almeamar H, O'Shea D, O'Toole D, Crowley R,

Keywords: pNET, pancreas, hypophosphataemia, osteomalacia, fgf23,

#3560 Nutritional status in patients with neuroendocrine tumors: A single ENETS Centre of Excellence experience

Introduction: Studies show that 14–68% of patients with neuroendocrine tumors (NETS) are at risk of or are malnourished. Patients’ dependent on NET type, primary or treatment are at risk of Vitamin B12, A, D E, iron deficiencies, pancreatic enzyme insufficiency (PEI) and a high HbA1c.

Conference:

Presenting Author:

Authors: Burke D, Almeamar H, O'Toole D, Barnes L, Crowley R,

Keywords: malnutrition, deficiencies, Pancreatic enzyme insufficiency, HbA1c's,

#3503 Neuroendocrine neoplasms of the biliary tract: A single ENETS Centre of Excellence case series

Introduction: Neuroendocrine neoplasms (NENs) of the biliary tract are rare. They represent approximately 2% of all NENs. They can arise from the gallbladder, extra-hepatic biliary tract (EHBD) and ampulla of Vater (AoV).

Conference:

Presenting Author: Ramlaul N

Authors: Ramlaul N, Almeamar H, Cullen L, Crowley R, Kruseman-Aretz N,

Keywords: biliary, neuroendocrine neoplasm, prognosis,

#3494 Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumors

Introduction: Lutetium Peptide Receptor Radio Nuclide Therapy (Lu-PRRT) is an effective treatment for progressive, metastatic, somatostatin-receptor-positive, well-differentiated Neuroendocrine Tumors (WD-NETs). It is generally well tolerated.

Conference:

Presenting Author:

Authors: Almeamar H, Cullen L, Murphy D, Crowley R, Skehan S,

Keywords: prrt, neuroendocrine tumor, efficacy, safety,

#2853 Succinate Dehydrogenase B (SDHB) Immunohistochemical Expression in Pancreatic Neuroendocrine Tumours and Correlation with Somatostatin Receptor Immunohistochemistry

Introduction: The established category of succinate dehydrogenase (SDH) deficient neoplasms includes several endocrine tumours with recent evidence that pancreatic neuroendocrine tumours (PNETs) could be included in this tumour group. The SDH complex is composed of four subunits (A-D) but loss of immunohistochemical (IHC) expression for SDHB indicates bi-allelic inactivation of any SDH component and is used as a marker for syndromic disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Swan N

Authors: Swan N, Nadeem N, Crowley R,

Keywords: succinate dehydrogenase, pancreatic neuroendocrine tumor, somatostatin receptor, immunohistochemistry,